Gregory Clarke to Depressive Disorder, Major
This is a "connection" page, showing publications Gregory Clarke has written about Depressive Disorder, Major.
Connection Strength
2.743
-
Cognitive Behavioral Therapy in Primary Care for Youth Declining Antidepressants: A Randomized Trial. Pediatrics. 2016 May; 137(5).
Score: 0.503
-
A randomized effectiveness trial of brief cognitive-behavioral therapy for depressed adolescents receiving antidepressant medication. J Am Acad Child Adolesc Psychiatry. 2005 Sep; 44(9):888-98.
Score: 0.240
-
Treatment for Adolescents With Depression Study (TADS): rationale, design, and methods. J Am Acad Child Adolesc Psychiatry. 2003 May; 42(5):531-42.
Score: 0.204
-
Group cognitive-behavioral treatment for depressed adolescent offspring of depressed parents in a health maintenance organization. J Am Acad Child Adolesc Psychiatry. 2002 Mar; 41(3):305-13.
Score: 0.188
-
Cognitive-behavioral treatment of adolescent depression: efficacy of acute group treatment and booster sessions. J Am Acad Child Adolesc Psychiatry. 1999 Mar; 38(3):272-9.
Score: 0.153
-
Neurocognitive Effects of Repetitive Transcranial Magnetic Stimulation With a 2-Coil Device in Treatment-Resistant Major Depressive Disorder. J ECT. 2018 Dec; 34(4):258-265.
Score: 0.150
-
Anhedonia predicts poorer recovery among youth with selective serotonin reuptake inhibitor treatment-resistant depression. J Am Acad Child Adolesc Psychiatry. 2012 Apr; 51(4):404-11.
Score: 0.094
-
Do sub-syndromal manic symptoms influence outcome in treatment resistant depression in adolescents? A latent class analysis from the TORDIA study. J Affect Disord. 2012 Apr; 138(1-2):86-95.
Score: 0.094
-
Out of the black box: treatment of resistant depression in adolescents and the antidepressant controversy. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):5-10.
Score: 0.093
-
Adjunctive sleep medications and depression outcome in the treatment of serotonin-selective reuptake inhibitor resistant depression in adolescents study. J Child Adolesc Psychopharmacol. 2012 Feb; 22(1):29-36.
Score: 0.093
-
Pharmacokinetically and clinician-determined adherence to an antidepressant regimen and clinical outcome in the TORDIA trial. J Am Acad Child Adolesc Psychiatry. 2011 May; 50(5):490-8.
Score: 0.088
-
Long-term outcome of adolescent depression initially resistant to selective serotonin reuptake inhibitor treatment: a follow-up study of the TORDIA sample. J Clin Psychiatry. 2011 Mar; 72(3):388-96.
Score: 0.088
-
Incremental cost-effectiveness of combined therapy vs medication only for youth with selective serotonin reuptake inhibitor-resistant depression: treatment of SSRI-resistant depression in adolescents trial findings. Arch Gen Psychiatry. 2011 Mar; 68(3):253-62.
Score: 0.088
-
Antidepressant exposure as a predictor of clinical outcomes in the Treatment of Resistant Depression in Adolescents (TORDIA) study. J Clin Psychopharmacol. 2011 Feb; 31(1):92-7.
Score: 0.087
-
Impact of physical and sexual abuse on treatment response in the Treatment of Resistant Depression in Adolescent Study (TORDIA). J Am Acad Child Adolesc Psychiatry. 2011 Mar; 50(3):293-301.
Score: 0.087
-
Substance use and the treatment of resistant depression in adolescents. J Am Acad Child Adolesc Psychiatry. 2009 Dec; 48(12):1182-92.
Score: 0.081
-
Effective components of TORDIA cognitive-behavioral therapy for adolescent depression: preliminary findings. J Consult Clin Psychol. 2009 Dec; 77(6):1033-41.
Score: 0.081
-
Predictors of spontaneous and systematically assessed suicidal adverse events in the treatment of SSRI-resistant depression in adolescents (TORDIA) study. Am J Psychiatry. 2009 Apr; 166(4):418-26.
Score: 0.076
-
Switching to another SSRI or to venlafaxine with or without cognitive behavioral therapy for adolescents with SSRI-resistant depression: the TORDIA randomized controlled trial. JAMA. 2008 Feb 27; 299(8):901-13.
Score: 0.071
-
Predicting time to recovery among depressed adolescents treated in two psychosocial group interventions. J Consult Clin Psychol. 2006 Feb; 74(1):80-8.
Score: 0.062
-
Potential mediators of cognitive-behavioral therapy for adolescents with comorbid major depression and conduct disorder. J Consult Clin Psychol. 2005 Feb; 73(1):38-46.
Score: 0.058
-
Effectiveness of antidepressant pharmacotherapy: the impact of medication compliance and patient education. Depress Anxiety. 2001; 13(1):1-10.
Score: 0.043
-
Psychoeducational treatment and prevention of depression: the "Coping with Depression" course thirty years later. Clin Psychol Rev. 2009 Jul; 29(5):449-58.
Score: 0.019